Pukhraj Rishi, MD
Retina Specialist · Omaha, NENPI 1275155038
Payments from drug & device makers
Across 30 payments — averaging $55.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$277
- Genentech USA, Inc.$184
- AbbVie$163
- Bausch & Lomb Americas Inc.$161
- Astellas Pharma US Inc$139
- Dutch Ophthalmic, USA$123
- plus $604 from 8 others
What the payments were for
- Food & beverage$1,652100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 4 | $277 |
| Genentech USA, Inc. | 2 | $184 |
| AbbVie(2 entities) | 4 | $163 |
| Bausch & Lomb Americas Inc. | 3 | $161 |
| Astellas Pharma US Inc | 2 | $139 |
| Dutch Ophthalmic, USA | 1 | $123 |
| Alimera Sciences, Inc. | 1 | $123 |
| Biogen | 1 | $98 |
| Oyster Point Pharma, Inc. | 5 | $94 |
| Genentech, Inc. | 2 | $84 |
| Iridex Corporation | 1 | $76 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $60 |
| Apellis Pharmaceuticals, Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$245
- VABYSMO$125
- EVA, combined machine$123
- Iluvien$123
- Izervay$121
- OZURDEX$117
How this compares
Too few retina specialist providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 73 | $2,416 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,053 |
| Ketorolac Tromethamine | 52 | $942 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $448 |
| MoxifloxacinMoxifloxacin Hcl | 16 | $429 |
| Latanoprost | 45 | $418 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $195 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Omaha
- John WelchHastings$10K
- William TerrellHastings$572
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.